TOPLINE: Compared with placebo, extended-release naltrexone-bupropion combination therapy reduced total fat mass and improved the lean-to-fat mass ratio in individuals with obesity or overweight and controlled hypertension, dyslipidemia, or both. METHODOLOGY: Although most weight-loss studies focus on overall body weight or body mass index (BMI) as outcomes…
